scholarly journals Case Report on Rom Exercises Effective in Reducing Pain and Discomfort in Hodgkin’s Lymphoma

2021 ◽  
pp. 19-23
Author(s):  
Viwek Nade ◽  
Vaishali Tembhare ◽  
Ruchira Ankar ◽  
Sheetal Sakharkar ◽  
Archana Dhengare ◽  
...  
Keyword(s):  
Lymph Nodes ◽  
Great Improvement ◽  
Hodgkin’S Lymphoma ◽  
Clinical Findings ◽  
Hodgkin's Lymphoma ◽  
Cell Transplant ◽  
Term Survival ◽  
Blood Biopsy ◽  
Lymph Node Examination

Introduction: Hodgkin lymphoma, which also accounts up 11% of all lymphomas, is named Hodgkin's disease. This malignant disease is known as the Reed-Sternberg-cell, which is situated in lymph-nodes and is characterized by the proliferation of irregular gait. The disease occurs more often in those between 15-30 years and over 55 and is doubling prevalent in women, in men and women. The sickness is bimodal age specific. The frequency in India is around 1 in 25,000 inhabitants. However, for all stages, long-term survival is around 80%. Clinical Findings: The onset of symptoms is usually insidious but usually used for frequent diagnosis are: Extension of lymph nodes in area of cervical, axillary or inguinal, extraordinary weight loss, Fatigue, Weakness, fever, chills, tachycardia, sweating or nocturnal sweat. Diagnostic Evaluation: Peripheral analysis of the blood, Biopsy of Excision of lymph node, Examination of bone marrow, Radiological study Therapeutic Management: Chemotherapy and radiation therapy or some may need immunotherapy or stem cell transplant. Outcome: After treatment, the child showed great improvement. Conclusion: A 11 year male child was admitted to pediatric ward no.22 in AVBRH on 25/05/2021 with a unique case of Hodgkin’s lymphoma with severe pain and discompfort. He was admitted in hospital and all investigation and treatment were started. After getting medical treatment and physiotherapy he shows great improvement and the treatment was still going on till my last date of care.

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4463-4463
Author(s):  
Emilia Cocorocchio ◽  
Fedro A. Peccatori ◽  
Federica Gigli ◽  
Simona Bassi ◽  
Luca Nassi ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Alkylating Agents ◽  
Performance Status ◽  
Low Risk ◽  
Hodgkin's Lymphoma ◽  
Cell Transplant ◽  
Bulky Disease ◽  
Before And After

Abstract Early stage HL patients (pts) benefit from a short course of chemotherapy combined with IF radiotherapy. In our previous experience six courses of VBM chemotherapy (Stanford regimen) were administered with IF radiotherapy. However, despite good clinical results, the schedule was modified in terms of total chemotherapy cycles delivered, in order to reduce the risk of long term toxicities. PET and CT scan were performed at staging to identify a low risk patients (pts) group. From May 2001 to November 2006, 32 treatment naïve Hodgkin’s lymphoma pts (18 male, 14 female) were treated with four courses of VBM chemotherapy (D1, 8: Vinblastine 6 mg/sm, Bleomycin 10 mg/sm, Methotrexate 30 mg/sm, repeated every 28 days) followed by IF radiotherapy. Median age was 37 years (range 16–73). Main histology was classical HL in 26 pts, while lymphocyte predominant was observed in 6 pts. Pts were all stage I-IIA (no bulky disease), no more than three sites involved, performance status 0–1 and ESR < 50. CT scans were performed before and after chemotherapy and radiotherapy. PET scans were performed before and after chemotherapy in 26 pts, and after radiotherapy if not performed before or in case of positivity after chemotherapy. Chemotherapy was usually well tolerated: three pts experienced G3-4 neutropenia while the main non- haematological toxicities recorded were G3 transaminitis in 3 pts and G1-2 neuroconstipation/abdominal pain in 18 pts. IF radiotherapy was performed one month after the last chemotherapy cycle; median dose administered was 30Gy (range 26–30.4). At the end of chemotherapy 7 pts were PET positive. While one patient developed progressive disease, the other six pts became negative after radiotherapy and are still in complete remission (CR). 29 pts (90%) completed the whole program obtaining a CR. Two pts progressed before radiotherapy, while one patient shifted to an anthracycline containing schedule after two cycles due to stable disease. With a median follow-up of 42 months (range: 7–73), all pts are alive. 1 out of 29 CR pts progressed and is now receiving intensive chemotherapy program with autologous stem cell transplant. In our experience four cycles of VBM chemotherapy combined with IF radiotherapy is an effective program. Furthermore this regimen that doesn’t contain alkylating agents or anthracyclines avoids alopecia and decreases the risk of long term toxicity. PET scan effectively helps to identify low risk early stage HL pts that can take advantage of this therapeutic approach.

TWO-DECADE EXPERIENCE AND LONG-TERM SURVIVAL IN PEDIATRIC NON-HODGKIN'S LYMPHOMA

PEDIATRICS ◽  
2008 ◽  
Vol 121 (Supplement 2) ◽  
pp. S121.3-S122
Author(s):  
Vassilios Papadakis ◽  
Agapi Parcharidou ◽  
Anna Paisiou ◽  
Natalia Tourkantoni ◽  
Sofia Papargyri ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival

PLoS ONE ◽  
2014 ◽  
Vol 9 (9) ◽  
pp. e106745 ◽  
Author(s):  
Corrado Tarella ◽  
Angela Gueli ◽  
Federica Delaini ◽  
Andrea Rossi ◽  
Anna Maria Barbui ◽  
...  
Keyword(s):  
T Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Refractory Disease ◽  
Term Survival ◽  
Long Term Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Evgeny Klyuchnikov ◽  
Ulrike Bacher ◽  
Nicolaus Kröger ◽  
Ilya Kazantsev ◽  
Tatjana Zabelina ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Special Focus ◽  
Term Survival

Despite the favorable prognosis of most patients with Hodgkin's Lymphoma (HL), 15–20% of patients remain refractory to chemoradiotherapy, and 20–40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage approach in this situation. Long-term survival of only 20% was reported for patients who failed this option. As some authors suggested the presence of a graft versus HL effect, allogeneic SCT was introduced as a further option. Myeloablative strategies were reported to be able to achieve cure in some younger patients, but high nonrelapse mortality remains a problem. Reduced intensity conditioning, in turn, was found to be associated with high posttransplant relapse rates. As there is currently no standard in the management of HL patients who failed autologous SCT, we here review the literature on allogeneic stem cell transplantation in HL patients with a special focus on the outcomes and risk factors being reported in the largest studies.

scholarly journals P.012 Treatment and long-term follow-up of primary CNS classical Hodgkin’s Lymphoma – a case report and review of the literature

2017 ◽  
Vol 44 (S2) ◽  
pp. S17-S17
Author(s):  
PA Szelemej ◽  
M Bigder ◽  
J Krcek
Keyword(s):  
Case Report ◽  
Hodgkin’S Lymphoma ◽  
Central Nervous System Involvement ◽  
Complete Response ◽  
Hodgkin's Lymphoma ◽  
Response To Treatment ◽  
Term Survival ◽  
Whole Brain Radiation ◽  
Long Term Follow Up

Background: Unlike non-Hodgkin’s lymphoma, central nervous system involvement with classical Hodgkin’s lymphoma is exceedingly rare, thus information regarding treatment and prognostication of the disease is lacking. Methods: This case report was prepared using hospital charts, and PubMed for the literature search. Our case was compared and contrasted against similar cases in the literature. Results: We present the case of a 47 year old female who presented with a left parietal dural-based lesion which proved to be Stage IE primary CNS classical Hodgkin’s lymphoma. After surgery and whole brain radiation therapy, the patient has remained in complete remission over nine years. Conclusions: Despite the dearth of information available regarding CNS Hodgkin’s lymphoma, our case is consistent with the findings in the literature that long-term survival is possible in patients achieving a complete response to treatment, especially in those patients who present with sole CNS involvement. To our knowledge, this represents the longest reported survival in the literature and contributes to our understanding of prognosis in patients with CNS Hodgkin’s lymphoma.

Early-Stage, Lymphocyte-Predominant Hodgkin's Lymphoma: Patient Outcomes From a Large, Single-Institution Series With Long Follow-Up

2010 ◽  
Vol 28 (1) ◽  
pp. 136-141 ◽  
Author(s):  
Ronald C. Chen ◽  
Michael S. Chin ◽  
Andrea K. Ng ◽  
Yang Feng ◽  
Donna Neuberg ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Early Stage ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Single Institution ◽  
Term Survival ◽  
Long Term Outcome ◽  
Extended Field

Purpose The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined. Treatment has become less aggressive over time in an attempt to reduce iatrogenic complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear. We present the long-term outcome of patients treated at a single institution. Patients and Methods The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005. Pathologic diagnosis for all patients was confirmed using standard criteria. Ninety-three patients received radiation therapy (RT) alone, 13 received RT with chemotherapy, and seven received chemotherapy alone. Among patients treated with RT, 25 received limited-field, 35 received regional-field, and 46 received extended-field RT. Results Median follow-up was 136 months. Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively. PFS and OS did not differ among patients who received limited-field, regional-field, or extended-field RT. In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment. Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99). The addition of chemotherapy to RT did not improve PFS or OS compared with RT alone. Conclusion RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease.

Sign in / Sign up

Export Citation Format

Share Document